-
The England Community Pharmacy Workforce Survey – what does the data tell us?
Wed 3rd June 2026
The PDA shares new analysis of the latest England Community Pharmacy Workforce Survey 2025 (CPWS) and places it in the wider context of the current and future pharmacy workforce in England.
-
PDA publishes new guidance on safer consultations and chaperone use for pharmacists
Tue 14th April 2026
The PDA has published new practice guidance reinforcing the importance of safer consultations for pharmacists, including the appropriate and routine use of chaperones.
-
PDA issues new supervision guidance to support pharmacists
Wed 18th March 2026
The PDA has today released a comprehensive summary guide and FAQs for pharmacists following the approval of The Human Medicines (Authorisation by Pharmacists and Supervision by Pharmacy Technicians) Order 2025, which builds on two decades of evolving interpretation of supervision in community pharmacy.
-
PDA contributes evidence to the House of Lords ‘Medicines Security’ inquiry
Mon 16th February 2026
The PDA recently provided written evidence to the House of Lords Public Services Committee’s inquiry into medicines supply chains, drawing attention to the impact of medicine shortages on both patient-facing pharmacists and the patients depending on their care.
-
PDA reminds members of the importance of appropriate monitoring when prescribing medication for ADHD
Wed 1st October 2025
Today marks the start of ADHD Awareness Month. As a growing number of members are working in ADHD clinics providing monitoring and dose titration, the PDA is taking this opportunity to alert members of the need to monitor patients carefully in accordance with NICE guidance when titrating doses upwards.
-
PDA reminds members about the risks associated with prolonged steroid use
Tue 9th September 2025
It can sometimes be easy to get caught up with issues related to new medicines and treatments and to forget about the safety risks that can accompany long-established and well-known products. Therefore, the PDA is taking the opportunity to remind all members of the hazards associated with prolonged steroid use.
-
PDA reminds members about the risks associated with prolonged steroid use
Tue 9th September 2025
It can sometimes be easy to get caught up with issues related to new medicines and treatments and to forget about the safety risks that can accompany long-established and well-known products. Therefore, the PDA is taking the opportunity to remind all members of the hazards associated with prolonged steroid use.
-
PDA responds to disability and ethnicity pay gap reporting
Tue 24th June 2025
The PDA has responded to the government’s consultation seeking views on how to introduce mandatory ethnicity and disability pay reporting for large employers (those with 250 or more employees).
-
Preliminary reflections and lessons from the Priory REACH Knowledge Transfer Partnership project
Thu 1st May 2025
The Priory REACH project (Research in Evaluation of improving Access to Cardiovascular disease and Healthy lifestyle checks) is a Knowledge Transfer Partnership (KTP) initiative led by Aston University in collaboration with the PDA.
-
PDA calls on members to share their views on changes to registration fees
Wed 12th February 2025
The General Pharmaceutical Council (GPhC) and the Pharmaceutical Society of Northern Ireland (PSNI) are consulting separately on proposed changes to registration fees for pharmacists. The payment of fees is mandatory to practice as a pharmacist.